On this weeks episode of the Business of Biotech, Bret Bostwick, M.D., Venture Partner at Breyer Capital, a family office, talks about his path from medical geneticist to CNS drug development and ...

Life sciences distribution is shifting toward AI-powered, resilient networks that improve speed, efficiency, compliance, and ...

On this weeks episode of the Business of Biotech, Simeon George, M.D., Cofounder and CEO at SR One Capital Management, returns to the show to talk about how SR One evaluates biotech investment targets ...

After 30 years of use in transplant medicine, EBV-specific T cells offer key lessons for safer, scalable allogeneic cell therapies, writes Ivan Horak, M.D.

Co-development is an established concept. The practical question is how early its logic should shape candidate selection, development planning, and portfolio governance. Combination therapy is routine ...

In pharma, an oncology drug approval is a significant milestone. I have spent enough time in this space to know that it is also the moment where a different, less visible problem begins. The community ...

For decades, the Silicon Valley playbook has dominated the narrative of innovation: a brilliant founder hacks together a minimum viable product in a garage, pitches a traditional venture capital (VC) ...

Life sciences companies operate at the leading edge of innovation, structuring high-value licensing, development, and outsourcing arrangements in a highly regulated environment. A persistent and often ...

"The pioneer spirit is still vigorous within this nation. Science offers a largely unexplored hinterland for the pioneer who has the tools for his task. Scientific progress is one essential key to our ...

In the United States, it has typically taken 10 to 15 years for breakthrough research to be adopted in real-world clinical settings: a decade or more between proving something saves lives and actually ...

Bouncing around the San Diego Convention Center’s 2.6 million square feet for four days is its own kind of flustery exercise, but in the age of Zoom it’s a more-than-welcome excursion. It’s hard to ...

The global pharmaceutical supply chain has been under intense scrutiny since the COVID-19 pandemic exposed its heavy reliance on concentrated Active Pharmaceutical Ingredient (API) manufacturing hubs.